IV vs. pill NAD supplements: what the science actually shows

What's this video probably claiming?

Based on the caption and hashtags, this creator is almost certainly arguing that IV NAD+ infusions are meaningfully superior to oral NAD+ precursor supplements, or possibly the reverse, that pills are underrated and IV is overhyped. The longevity, menopause, and metabolism hashtags suggest she's pitching NAD+ as a broad wellness intervention for energy, hormonal aging, and cellular repair. Expect claims that IV bypasses digestion for better bioavailability, that oral NMN or NR raises blood NAD+ levels, and some framing around mitochondrial function or DNA repair. The menopause angle is a tell: NAD+ levels do decline with age, and some clinicians are marketing IV infusions specifically to perimenopausal women as a fatigue or brain fog fix. None of that is established in clinical trials. It is important to note we do not have the actual transcript yet, so this is an evidence-based preview of the topic, not a line-by-line rebuttal.

What does the science actually show?

Here is where things get genuinely interesting and more complicated than either camp wants to admit. Oral NMN (nicotinamide mononucleotide) at 300-600 mg/day does raise blood NAD+ levels in humans. Yoshino et al. (2021, Science) showed that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity in postmenopausal women with prediabetes, but did not improve body composition or VO2 max. Trammell et al. (2016, Nature Communications) confirmed that NR (nicotinamide riboside) at 1000 mg/day raised whole blood NAD+ by roughly 2.7-fold over baseline. On the IV side, there is almost no published human RCT data. Most IV NAD+ protocols are extrapolated from animal models or small addiction medicine case series. The assumption that higher plasma NAD+ from IV translates to meaningful cellular or tissue-level changes in healthy adults has not been tested in any adequately powered trial.

Where does the social media noise diverge from clinical reality?

The gap is significant. IV NAD+ clinics routinely charge $500-$1,500 per infusion and imply dramatic anti-aging or cognitive benefits that have zero RCT support in healthy adults. The bioavailability argument is real but overstated: yes, IV bypasses first-pass metabolism, but oral NMN and NR do raise systemic NAD+ meaningfully. The question that nobody on TikTok is asking is whether raising NAD+ in blood or muscle actually produces the downstream benefits, like improved mitochondrial function or reduced biological aging, that the longevity narrative promises. Martens et al. (2023, Nature Aging) found NMN supplementation improved walking speed in older adults but effects were modest. Mehmel et al. (2020, Nutrients) reviewed safety and found oral precursors are generally well-tolerated. IV NAD+ can cause flushing, nausea, chest tightness, and rarely arrhythmia during infusion, none of which IV advocates tend to mention prominently.

What should you actually know?

If you are considering NAD+ supplementation in any form, the honest summary is this: oral NMN and NR have more published human data than IV NAD+, not less. The bioavailability advantage of IV is real but clinically unproven to matter at the outcome level. No study has shown IV NAD+ outperforms oral precursors on any validated health endpoint in healthy adults. The menopause-specific evidence is limited to one notable NMN trial (Yoshino 2021) in prediabetic women, not healthy perimenopausal women. If a clinician or creator is recommending IV NAD+ for longevity, metabolism, or menopause symptoms without disclosing that this is off-label with minimal supporting trial data, that is a meaningful omission. Oral precursors at studied doses are a more evidence-supported starting point. Talk to a physician before starting either, especially if you have cardiac or metabolic conditions, because the safety profile of frequent IV NAD+ infusions in general populations is genuinely unknown.